Biotech bubble

Axovant Sciences Ltd (NYSE: AXON) nearly doubled during its first few hours of trading Thursday, stirring comments about a biotech bubble. The company acquired its single product, a prospective treatment for Alzheimer's disease, for $5 million from GlaxoSmithKline plc (ADR) (NYSE: GSK) in December...

By Atlas Capital From time to time, humankind has had periods of arrogance where society as a whole believes that many (if not all) of life's mysteries have been solved. Such was a time in the 1800s when most believed they had advanced as far as possible…just before the Industrial...